MedPath

Investigating the Production of Lipoproteins and Acetyl-CoA During a Ketogenic Diet

Not Applicable
Completed
Conditions
Cholesterol Metabolism
Ketone Metabolism
Interventions
Other: Very low carbohydrate diet
Other: Standard American diet
Registration Number
NCT03901014
Lead Sponsor
Touro University, California
Brief Summary

The purpose of this study is to understand how the reduction in dietary carbohydrates in a very-low carbohydrate ketogenic diet impacts the synthesis of cholesterol, fatty acid, and ketones, and the turnover rate of VLDL and chylomicron particles.

Detailed Description

Participants will consume a standard American diet for one week followed by a very-low carbohydrate ketogenic diet (VLCKD, \<50 grams carbohydrate/day) for two weeks. Participants will undergo an oral stable isotope tracer study during each diet to measure de novo synthesis of fatty acid, cholesterol, ketone bodies, and for measurement of apolipoprotein B and triglyceride kinetics.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
4
Inclusion Criteria
  • Male
  • 18-50 years old
Exclusion Criteria
  • Use of nicotine products
  • Has dietary restrictions
  • Lactose intolerance
  • History of GI disorders, diabetes, liver, kidney, or thyroid disorders
  • Taking hypolipidemic, anti-diabetic, anti-hypertensive, or anti-depression medication
  • Screening plasma triglyceride < 50mg/dl or >500mg/dl
  • Screening glucose > 125mg/dl
  • Screening total and LDL-Cholesterol over 95th %tile for age and sex
  • BP > 160/95 mmHg
  • Weight loss/gain > 5% in the previous 3 months (self-reported)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Very low carbohydrate dietVery low carbohydrate diet2 week very low carbohydrate ketogenic diet
Baseline dietStandard American diet1 week baseline diet
Primary Outcome Measures
NameTimeMethod
Change in total cholesterolDay 3-7 to Day 17-21

Change in serum total cholesterol between Day 3-7 (average value) to Day 17-21 (average value)

Change in low density lipoprotein (LDL) cholesterolDay 3-7 to Day 17-21

Change in serum LDL cholesterol between Day 3-7 (average value) to Day 17-21 (average value)

Change in high density lipoprotein (HDL) cholesterolDay 3-7 to Day 17-21

Change in serum HDL cholesterol between Day 3-7 (average value) to Day 17-21 (average value)

Change in apolipoprotein B (apoB) kineticsDay 3-7 to Day 17-21

Change in apoB turnover rates in LDL and very low density lipoprotein plasma fractions as measured using 2H2 leucine incorporation into apoB and mathematical modeling

Secondary Outcome Measures
NameTimeMethod
Change in fractional hepatic de novo lipogenesisDay 3 to Day 17

Measured by the detection of incorporated 1-13C sodium acetate into palmitate in triglyceride rich lipoproteins (TRL)

Change in fractional cholesterol synthesisDay 3 to Day 17

Measured by the detection of incorporated 1-13C sodium acetate into cholesterol in plasma

Change in ketone body synthesisDay 3 to Day 17

Measured by the detection of incorporated 1-13C sodium acetate into ketone bodies in plasma

Change in TRL-triglyceride kineticsDay 3 to Day 17

Change in TRL- triglyceride assembly rates as measured using 2-13C glycerol and mathematical modeling

Change in triglyceride lipolysisDay 3 to Day 17

Measured by the dilution of administered 2-13C glycerol in plasma

Change in serum glucose concentrationDay 3 to Day 17

Change in fasting and postprandial serum glucose levels

Change in serum free fatty acid concentrationDay 3 to Day 17

Change in fasting and postprandial serum free fatty acid levels

Change in serum insulin concentrationDay 3 to Day 17

Change in fasting and postprandial serum insulin levels

Change in serum ketone body concentrationDay 3 to Day 17

Change in fasting and postprandial ketone body levels

Trial Locations

Locations (1)

Touro University California

🇺🇸

Vallejo, California, United States

© Copyright 2025. All Rights Reserved by MedPath